莫西沙星治疗腹腔内感染的药物学研究

Clinical Application of Moxifloxacin in the Treatment of Intra-abdominal Bacterial Infections

目的：探讨莫西沙星注射液应用在中重度急性腹腔感染治疗中的临床疗效与安全性。方法：共纳入31例患者，随机分为罗氏芬加甲硝唑治疗组（对照），罗氏芬2g，每日1次，甲硝唑0．5g，每日2次；莫西沙星治疗组，莫西沙星400mg，每日1次，均为静脉滴注，疗程为7～14天。结果：两组的痊愈率分别为80％和81．25％，有效率分别为86．67％和87．5％，细菌清除率分别为91．67％与90％。组间比较差异均无统计学意义。两组的不良反应发生分别为2／15和1／16，主要表现为局部刺激及转氨酶升高等。结论：莫西沙星注射液治疗中重度腹腔细菌感染疗效确切，安全性好。

Objective.. To investigate the clinical efficacy and safety of moxifloxaein injection in treatment of acute moderate and severe abdominal bacterial infections. Methods： A randomized clinical study was conducted. Moxifloxacin 400mg Qd in the study group, or eeftriaxone 2 g qd and metronidazole 0.5 g q 12 h in the control group, for 7 to 14 days. Results： Thirty-one patients were enrolled in the study, 15 were in moxifloxaein group and 16 in control group. The clinical cure rates and effective rates were 80 % and 86. 67% in moxifloxacin group, and 81.25 % and 87.5 % in control group respectively. The bacterial eradications rates were 91. 67% and 90% respectively. Adverse events were mild in two groups. Conclusion： Moxifloxacin is effective and safe for the treatment of acute moderate and severe abdominal bacterial infections.